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Abstract
Objectives. RA patients receiving TNF inhibitors (TNFi) usually maintain their initial doses. The aim of the
Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate
whether tapering TNFi doses causes loss of clinical response.
Methods. We enrolled RA patients receiving etanercept or adalimumab and a DMARD with DAS28 under
3.2 for over 3 months. Initially (months 06) patients were randomized to control (constant TNFi) or two
experimental groups (tapering TNFi by 33 or 66%). Subsequently (months 612) control subjects were
randomized to taper TNFi by 33 or 66%. Disease flares (DAS28 increasing 50.6 with at least one add-
itional swollen joint) were the primary outcome.
Results. Two hundred and forty-four patients were screened, 103 randomized and 97 treated. In months
06 there were 8/50 (16%) flares in controls, 3/26 (12%) with 33% tapering and 6/21 (29%) with 66%
tapering. Multivariate Cox analysis showed time to flare was unchanged with 33% tapering but was
reduced with 66% tapering compared with controls (adjusted hazard ratio 2.81, 95% CI: 0.99, 7.94;
P = 0.051). Analysing all tapered patients after controls were re-randomized (months 612) showed differ-
ences between groups: there were 6/48 (13%) flares with 33% tapering and 14/39 (36%) with 66%
tapering. Multivariate Cox analysis showed 66% tapering reduced time to flare (adjusted hazard ratio
3.47, 95% CI: 1.26, 9.58; P = 0.016).
Conclusion. Tapering TNFi by 33% has no impact on disease flares and appears practical in patients in
sustained remission and low disease activity states.
Trail registration: EudraCT, https://www.clinicaltrialsregister.eu, 2010-020738-24; ISRCTN registry,
https://www.isrctn.com, 28955701
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Rheumatology key messages
. Tapering TNF inhibitors in RA patients by 33% over 6 months did not reduce time to disease flare.
. By 12 months, 45% of RA patients who tapered TNF inhibitor treatment were able to stop it entirely.
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Introduction
Trials and observational studies underpinning the regula-
tory approval of TNF inhibitors (TNFi) for treating RA pa-
tients focus on initial efficacy and long-term safety [13].
What to do after achieving disease control is another
question. Currently doses of TNFi effective in inducing re-
sponses in active RA are continued to maintain control,
despite limited evidence they are needed. Maintaining dis-
ease control maintained with lower doses of TNFi should
increase their cost-effectiveness.
The Optimizing Treatment with TNFi in RA (OPTTIRA)
trial was designed when there was limited information
about tapering TNF inhibitor in RA patients with good
treatment responses. Subsequently several observational
studies and trials evaluated tapering. Systematic reviews
of reports before 2015 [47] found evidence supporting
TNF tapering. The Cochrane systematic review, which
focused exclusively on trials [7], found tapering gave simi-
lar outcomes to continuing standard doses of adalimumab
and etanercept; complete discontinuation increased
flares. Another seven trials [814] were published after
these systematic reviews were completed. One trial [12]
concluded disease activity guided adalimumab or etaner-
cept dose reductions were non-inferior to usual care for
major flares; dose reduction or stopping was possible in
two-thirds of patients. Overall the evidence suggests
tapering does not substantially increase flares; stopping
completely may do so. Recent observational studies sup-
port dose reduction [1517]. Reviews by Schett et al. [18]
and Edwards et al. [19] highlighted the importance of
TNF inhibitor tapering and minimizing other long-term
DMARDs. However, there remain uncertainties about
which patients should have their TNFi tapered and
whether all tapering regimens are similar.
OPTTIRA is a randomized trial evaluating two tapering
regimens in RA. It recruited patients showing EULAR good
responses to TNFi [20] and compared tapering with con-
tinuing standard doses. Tapering regimens reduced
doses to one-third and two-thirds initial response induc-
tion doses of adalimumab or etanercept over 6 months.
OPTTIRA also examined subsequently stopping TNFi
completely. It used time to flare to assess the effects of
TNF inhibitor tapering. Flares occurred when the DAS28
joints was over 3.2 and increased by 0.6 or more.
Methods
Design
OPTTIRA was an open label, 6-month multicentre proof of
principle trial with a subsequent 6-month exploratory
phase for patients who completed the initial trial.
OPTTIRA enrolled RA patients achieving good responses
[20] with low disease activity or remission taking standard
TNFi doses and receiving one or more DMARDs.
Participants
Patients receiving TNFi had met existing English criteria
from the National Institute for Health and Clinical
Excellence for these agents. The criteria have changed
with time; they included failing to respond to MTX and
another DMARD [21]. These criteria meant all patients
had established RA. Patients had also achieved sustained
good responses with DAS28 scores of 43.2 without in-
creases of> 0.6 during the previous 3 months.
Interventions
Patients were taking etanercept or adalimumab; their
existing TNFi were the trial investigational medicinal
products.
The proof of principle trial (months 06) compared three
groups: experimental group 1: TNF inhibitor tapered by
33% initial dose; experimental group 2: TNF inhibitor
tapered by 66% initial dose; control group: continued
standard doses. Supplementary Tables S1 and S2, avail-
able at Rheumatology Online, show reducing etanercept
and adalimumab dosing schedules.
In the exploratory phase (months 712) patients in ex-
perimental groups increased times between injections
until they stopped. Patients in the control group were fur-
ther randomized into two groups: control group A had
TNFi tapered by 33% initial dose; control group B had
TNFi tapered by 66% initial dose. Supplementary Tables
S3 and S4, available at Rheumatology Online, show the
dosing schedules. The tapering schedules reflected
standard dosing regimens related to the half-lives of the
drugs.
Primary outcome
The primary outcome was time to first flare, defined as an
increase in DAS28 scores50.6 resulting in a DAS28 >3.2
together with an increase in the swollen joint count; both
had to be present on two occasions at least 1 week apart.
An increase in DAS28 score51.2 resulting in DAS28 >3.2
was defined as flare irrespective of changes in swollen
joints. These criteria reflect the subsequently developed
DAS28 flare definitions proposed by OMERACT [22] and
supported by the Cochrane group [7]. Patients were as-
sessed 3 monthly and telephoned by their Research
Nurse monthly to check their disease control. Patients
who considered they were experiencing a flare were
seen urgently (within 2 weeks).
Secondary outcomes
HAQ, EuroQol 5-dimension scale (EQ5D-3L), Medical
Outcomes Study 36-Item Short Form Health Survey (SF-
36) and Functional Assessment of Chronic Illness Therapy
were assessed at 0, 3, 6 and 12 months. X-rays of the
hands (including wrists) and feet were taken at 0, 6 and
12 months with digitized X-rays read by an experienced
observer (D.L.S.) blinded to treatment using modified
Larsen scores. Every 3 months disease activity assess-
ments recorded tender and swollen joint counts
(28 joints), ESR, patients’ global assessments of disease
activity (100 mm visual analogue scale) and DAS for 28
joints together with details of medication and adverse
effects. An anonymized electronic data capture system
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collected clinical data except X-rays (http://www.medsci-
net.net).
Sample size
The TEMPO trial showed 15% of patients on etanercept
with MTX withdrew annually (flares and other problems)
[23, 24]. The BSR Biologics Register [25] showed 12% of
patients withdraw annually from TNFi. These results sug-
gested 1215% of patients taking TNFi flared annually;
during the 6 months proof of principle trial the likelihood
of flare was 7.5%. Studying 30 patients in one tapering
group would show a significant difference at the 5% level
with 80% power if over 42% of patients flared; such a
difference would mean tapering was not clinically useful.
Therefore a proof of principle study of 30 patients in each
group should provide sufficient information to reject the
concept if it is clearly ineffective, as well as giving enough
data to design larger trials if needed. We allowed for 10%
of patients not continuing in the trial and therefore aimed
to recruit 33 patients in each group with a total study size
of 99 patients.
The randomization algorithm considered patients in
both proof of principle trial and the exploratory study
taking different biologics. Consequently the randomization
ratio generated was 1:1:2; we recruited twice as many to
the control group than the initial tapering groups in the
proof of principle trial.
Randomization
Potentially eligible patients were screened and reasons for
non-entry recorded. The electronic data capture system
(MedSciNet) randomized patients using minimization into ex-
perimental and control groups, stratified by TNF inhibitor (eta-
nercept or adalimumab) using randomly permuted blocks.
Recruiting staff were blinded to allocation sequences.
Blinding
OPTTIRA was unblinded for assessors because it used
treatment-specific algorithms with the adjustment of mul-
tiple dosing intervals of the drugs. Disability and quality of
life were assessed by patients and X-ray reading was
blinded.
Statistical methods
Randomized patients accepting their allocated treatment
were analysed on an intention-to-treat basis. Data man-
agement and analyses used Stata (version 14.0,
StataCorp, College Station, TX, USA). Baseline character-
istics were summarized by randomization group as means
and standard deviations (normally distributed variables),
medians and interquartile ranges (non-normally distribu-
ted variables) and frequencies and percentages (categor-
ical variables). Serious adverse event rates in each arm
were compared with controls.
Separate analysis was performed for the proof of prin-
ciple phase (06 months) and the exploratory phase
(612 months). The primary outcome was time to flare
(months) for patients randomized to control, 33% taper
or 66% taper, defined as the time from study entry to
the first flare. Patients without flares, who withdrew or
were lost to follow-up, were censored at the time of
their last visit. Eight out of 97 patients were lost to
follow-up (supplementary Fig. S1, available at
Rheumatology Online). KaplanMeier curves and the log-
rank test compared randomized groups. Survival analysis
analysed time to flare. The validity of the assumption of
proportionality required for Cox regression was investi-
gated graphically (using NelsonAalen plots) as well as
using Schoenfeld residuals in the final Cox models.
Secondary outcomes were analysed using mixed
models to estimate treatment effects including baseline
values as covariates. Working correlation matrices were
unstructured, which is not unduly restrictive given that
measurements are only taken at three time points. The
sandwich estimator of covariance matrix was used in
order to obtain appropriate (consistent) estimates of pre-
cision. All P-values were two sided.
Ethical review
The North West London Research Ethics Committee
approved OPTTIRA (REC Ref: 10/H0720/69). All enrolled
patients gave written informed consent. The trial was
registered with the UK Clinical Research Network and
other relevant organizations (EudraCT number: 2010-
020738-24; ISRCTN: 28955701).
Results
Patients and treatments
Recruitment
Between April 2011 and June 2013, 244 patients were
screened, 103 randomized and 97 accepted their allo-
cated treatment (supplementary Fig. S1, available at
Rheumatology Online).
Treatment at baseline
All patients received disease modifying drugs: 82 had
DMARD monotherapy; 15 received combination DMARDs.
The DMARDs comprised MTX (81 patients), HCQ (18), SSZ
(11) and LEF (4). All patients received etanercept (43 pa-
tients) or adalimumab (54). Two patients were taking pred-
nisolone. The mean baseline treatment duration was
5.8 years (range 0.515.1 years).
Proof of principle phase
Of the patients, 50/97 were randomized to continue bio-
logic at unchanged dosages, 26/97 to taper biologics by
33% and 21/97 to taper by 66%; 74/97 patients com-
pleted 6 months’ treatment, 8/97 were lost to follow-up
and 15/97 discontinued tapering but were followed up;
13/97 patients stopped treatment for flares, 1/97 stopped
for drug toxicity and 9/97 stopped for other reasons
including 1/97 for disease progression and 5/97 at the
patients’ own request.
Exploratory phase
Of the patients randomized to continue biologics at un-
changed doses who completed the 6-month proof of
www.rheumatology.oxfordjournals.org 3
Optimizing treatment with TNFi in RA
Downloaded from https://academic.oup.com/rheumatology/article-abstract/doi/10.1093/rheumatology/kex315/4084282/Optimizing-treatment-with-tumour-necrosis-factor
by University College London user
on 19 October 2017
principle trial, 40/50 were re-randomized in the explora-
tory phase: 22/40 tapered by 33% and 18/40 tapered by
66%; 32/40 patients completed 6 months’ treatment and
8/40 patients discontinued tapering but were followed up;
5/40 stopped treatment for flares, 2/40 had disease pro-
gression and 1/40 stopped at the patients’ own request.
The 34 patients who had tapered for 6 months and con-
tinued on the treatment schedule in the proof of principle
trial tapered further until their biologics were completely
stopped by 6 months; 21/34 completed 6 months’ treat-
ment, 2/34 were lost to follow-up and 11/34 discontinued
tapering but were followed up. All 13/34 patients stopping
treatment did so because of flares.
Baseline data and numbers analysed
Demographic and disease assessments were similar in all
patient groups (Table 1). The patients had established RA
(median disease duration 11.3 years) with low DAS28-ESR
(median 2.0) and low HAQ scores (median 0.50). All trea-
ted patients were analysed in the proof of principle trial.
Primary outcome
Proof of principle phase
Seventeen patients flared comprising 8/50 (16%) control
patients, 3/26 (12%) patients tapering by 33% and 6/21
(29%) patients tapering by 66% (Table 2). Univariate and
multivariate Cox analysis of the intention to treat popula-
tion (Table 2) showed no evidence 33% tapering reduced
time to flare (adjusted hazard ratio 0.87, 95% CI: 0.22,
3.88; P = 0.835), but 66% tapering significantly reduced
time to flare compared with controls (adjusted hazard
ratio 2.81, 95% CI: 0.99, 7.94; P = 0.051). Figure 1
shows KaplanMeier survival curves comparing groups.
Exploratory phase—re-randomized patients
Eleven patients flared: 3/22 (14%) patients tapering by
33% and 8/18 (44%) tapering by 66% (Table 2).
Univariate and multivariate Cox analysis showed 66%
tapering significantly increased the risk of flare compared
with 33% tapering (adjusted hazard ratio 5.10, 95% CI:
1.81, 21.95; P = 0.029).
Combined tapering groups. Results from re-randomized
initial controls were combined with the tapering groups in
the proof of principle trial to provide a detailed compari-
son of time to flare in the two tapering regimens over
6 months. Six of forty-eight (13%) patients tapering by
33% flared compared with 14/39 (36%) patients tapering
by 66% (Table 2). Multivariate Cox analysis showed 66%
tapering significantly increased the risk of flare compared
with 33% tapering (adjusted hazard ratio 3.47, 95% CI:
1.26, 9.58; P = 0.016).
Secondary outcomes in proof of principle trial
Longitudinal analysis of changes within the first 6 months
in all treated patients (Table 3) showed little evidence that
33% tapering had any impact on clinical or functional as-
sessments. However, 66% tapering led to significant wor-
sening in tender and swollen joint counts, C-reactive
protein levels and ESR and DAS28 ESR but not DAS28
CRP scores. An interesting finding is that patient related
outcome measures including patient global score, HAQ,
EQ5D-3L, visual analogue scale (VAS) pain and functional
assessment of chronic illness therapy fatigue scores were
unaffected by tapering, including tapering by 66%.
Assessor global scores and Larsen scores also did not
differ between groups. Details of secondary outcomes
are shown in supplementary Table S5, available at
Rheumatology Online.
Impact of flares in proof of principle phase
The effects of flares, irrespective of treatment group, on
6-month outcomes were assessed in linear regression
models adjusted for age, gender and disease duration.
DAS28 scores were higher in patients who flared (0.85,
95% CI: 0.44, 1.26; P< 0.001) and EQ5D scores were
lower (0.12, 95% CI: 0.23, 0.02; P = 0.022), but
HAQ scores were unaffected (0.92, 95% CI: 0.19, 0.22;
P = 0.87).
Discontinuing TNF inhibitor
Thirty-four patients who tapered biologics in the proof of
principle trial (21 with 33% tapering; 13 with 66% taper-
ing) further tapered treatment until they stopped TNF in-
hibitor over 6 months in the exploratory study. Thirteen of
thirty-four (38%) flared and 21/34 (62%) did not flare.
Consequently 21/47 (45%) patients who started tapering
in the proof of principle trial stopped TNF inhibitor by
12 months; 21/47 (45%) had flared and 5/47 (11%) had
stopped tapering for other reasons. The 21 patients who
stopped TNF inhibitor without flaring had initial DAS28
score of 1.51 (95% CI: 1.14, 2.65) and 12 month DAS28
scores of 2.27 (95% CI: 1.71, 3.98). Their initial HAQ was
0.65 (95% CI: 0.33, 0.99) and the 12 month HAQ 0.75
(95% CI: 0.42, 1.17).
Flares in patient subgroups
The flare rate for patients receiving adalimumab, 18/54
(33%), was significantly lower (2 = 3.99, degrees of free-
dom (DF) = 1, P = 0.050) than for patients receiving
etanercept, 23/43 (53%).
At baseline 74 patients were in remission and had
DAS28 scores under 2.6; 27/74 (36%) of these patients
flared. There were 23 patients with low disease activity
(DAS28 score 2.63.2) and 14/23 (61%) of these flared.
The risk of flare was therefore significantly higher for pa-
tients with low disease activity at baseline (2 = 4.3, DF = 1,
P = 0.039) than for those in remission.
Adverse events
Overall there were 443 adverse events; 76/97 (78%) pa-
tients had one or more events; 47/97 (48%) patients had
an adverse event in the first 6 months and 29/89 (33%) in
the second 6 months (Table 4); 4/97 (4%) of patients had a
serious adverse event, 3 in the first 6 months and 1 in the
second 6 months; 220/443 (50%) of adverse events
involved the musculoskeletal system and only 223/443
(50%) involved other systems. No relationships were iden-
tified between treatment tapering and adverse events.
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Discussion
OPTTIRA shows reducing TNF inhibitor doses by one-
third in RA patients with stable low disease activity or re-
mission also taking DMARDs has no impact on disease
activity or the frequency of flares. However, the limited
number of patients included in each arm restricts the im-
portance of its finding for clinical practice. Most patients
were in remission; there was some evidence patients with
low disease activity scores had more flares. Greater
TABLE 1 Baseline demographic and clinical characteristics
33% tapering 66% tapering Controls Total
n = 26 n = 21 n = 50 n = 97
Demographic variables
Age, mean (S.D.), years 59 (11) 58 (9) 56 (12) 57 (11)
Height, mean (S.D.), m 1.66 (0.08) 1.67 (0.08) 1.66 (0.09) 1.66 (0.08)
Weight, mean (S.D.), kg 74.8 (15.6) 70.1 (14.4) 74.3 (16.1) 73.5 (15.5)
BMI, kg/m2 26.9 (21.931.6) 24.5 (22.627.8) 25.3 (23.129.7) 25.4 (22.629.4)
Disease duration, years 11.2 (6.219.0) 10.6 (7.315.9) 11.9 (7.316.7) 11.3 (7.316.7)
Female gender, n (%) 19 (73) 15 (71) 38 (76) 72 (74)
Smoking status, n (%)
Ex 9 (43) 7 (41) 16 (35) 32 (38)
Current 2 (9) 3 (18) 7 (15) 12 (14)
Clinical variables
Tender joint counts, 28 joints 0 (00) 0 (00) 0 (01.00) 0 (01.00)
Swollen joint counts, 28 joints 0 (00) 0 (00) 0 (00) 0 (00)
Tender joint counts, 68 joints 0 (01.00) 0 (02.00) 0 (02.00) 0 (02.00)
Swollen joint counts, 66 joints 0 (00) 0 (00) 0 (00) 0 (00)
ESR, mm/h 6 (424) 8 (419) 9 (520) 8 (519)
CRP, mg/l 5 (26) 4 (25) 5 (27) 5 (26)
Assessor global rating, mm 3 (010) 4 (110) 3 (19) 3 (110)
Patient global assessment, mm 9 (115) 4 (116) 5 (216) 5 (116)
DAS28 ESR 1.7 (1.12.6) 1.9 (1.32.6) 2.1 (1.42.6) 2.0 (1.32.6)
DAS28 CRP 2.3 (2.02.5) 2.2 (1.72.5) 2.1 (1.92.5) 2.2 (1.92.5)
HAQ 0.75 (0.131.38) 0.38 (0.00.88) 0.50 (0.131.50) 0.50 (0.131.38)
EQ5D-3L 0.79 (0.661.00) 0.80 (0.691.00) 0.74 (0.591.00) 0.76 (0.661.00)
Pain visual analogue score, mm 6 (110) 8 (119) 5 (025) 5 (119)
FACIT Fatigue Scale 40 (31 45) 41 (3546) 42 (3646) 41 (3546)
Larsen score 33 (1276) 34 (1763) 66 (2989) 51 (1682)
SF-36
PCS 43 (3851) 46 (3751) 44 (3252) 45 (3452)
MCS 51 (4358) 57 (4860) 58 (5261) 57 (4960)
Values shown as median (interquartile range) unless otherwise stated. EQ5D-3L: EuroQol 5-dimension scale; FACIT:
Functional Assessment of Chronic Illness Therapy; MCS: mental health summary score; PCS: physical health summary
score; SF-36: 36-Item Short Form Health Survey.
TABLE 2 Flare rates and univariate and multivariate cox analyses in intention to treat analysis and exploratory studies
Flares, n (%)
Unadjusted Adjusteda
HR (95% CI) P-value HR (95% CI) P-value
Intention to treat analysis (n = 97) Control 8/50 (16) Reference Reference
33% tapering 3/26 (12) 0.90 (0.23, 3.48) 0.873 0.87 (0.22, 3.88) 0.835
66% tapering 6/21 (29) 2.52 (0.85, 7.48) 0.097 2.81 (0.99, 7.94) 0.051
Exploratory study (n = 40) 33% tapering 3/22 (14) Reference Reference
66% tapering 8/18 (44) 4.16 (1.08, 15.99) 0.038 5.10 (1.18, 21.95) 0.029
Combined tapering (n = 87) 33% tapering 6/48 (13) Reference Reference
66% tapering 14/39 (36) 3.29(1.26, 8.63) 0.015 3.47(1.26, 9.58) 0.016
aThe multivariate model was adjusted for age at registration, gender and disease duration.
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reductions in TNF inhibitor doses led to more flares and
higher disease activity levels but had no impact on dis-
ability. TNFi could be stopped in many patients without
major negative impacts upon their disease.
The balance of evidence from OPTTIRA and previous
trials and observational studies of tapering and stopping
TNFi is that modest dose reduction is possible in RA pa-
tients with good responses to TNFi who remain on con-
ventional DMARDs. Indeed there is little evidence
favouring maintaining standard doses in such patients.
OPTTIRA showed that reducing biologic doses by one-
third had no impact on clinical, functional or health
status assessments and did not result in more flares.
TNFi are expensive with uncertainties about their overall
cost-effectiveness [26, 27] and in patients with good
responses tapering appears less expensive than maintain-
ing full doses without major negative impacts.
The evidence favouring major reductions in TNF inhibi-
tor dose, such as reducing by two-thirds, is less clear-cut.
OPTTIRA, other trials and observational studies all found
this gives more flares and worse clinical and health status.
However, the negative impacts are modest and in some
patients treatment can be stopped without obvious disad-
vantages. Considering stopping treatment may be rea-
sonable in selected cases.
Reductions in TNF inhibitor doses in stable RA have not
been approved by regulatory agencies and therefore or-
ganizations like the National Institute for Health and
Clinical Excellence cannot recommend such approaches
[28]. Nevertheless, individual clinicians may decide, based
on overall assessments of risks and benefits, to offer dose
reductions to some patients. The impact of tapering TNFi
is broadly similar to reducing the doses of conventional
DMARDs; reducing MTX doses can be achieved in some
patients but stopping treatment increases flares. Defining
patients likely to flare is an important future research goal.
Adverse events were common in OPTTIRA and often
involved the musculoskeletal system. Only four were ser-
ious events and these were unrelated to tapering or stop-
ping treatment. The serious adverse event rate was similar
to that in the systematic review of tapering by van
Herwaarden et al. [7] who reported 5% of patients had
serious adverse events. Such adverse event rates are
likely to be commonplace in treated RA patients.
TNFi are expensive, and while using effective biosimi-
lars [29] will reduce costs, such biologic treatments will
never become inexpensive. Consequently the clinical and
the economic benefits of good responders remaining on
standard doses of TNFi will diverge. As the disadvantages
of tapering and trying to stop TNFi are relatively small,
clinicians and healthcare funders may consider it prefer-
able to explore reducing and stopping treatment when
patients achieve good disease control. In early RA, using
biologics initially may result in sustained biologic-free and
drug-free remissions [30, 31]; OPTTIRA and similar trials
have not evaluated this possibility. Nevertheless it may be
important because achieving sustained deep remission
may be of critical consequence in early disease.
Our trial had several strengths. It involved a range of RA
patients across multiple English centres, making its find-
ings likely to be generalizable. It evaluated two tapering
regimens and stopping treatment, ensuring several stra-
tegies for reducing TNF inhibitor doses. It had several
weaknesses. First, it was relatively small and enrolled
only 97 patients. Its lack of power precludes robust con-
clusions in secondary analyses evaluating the impact of
tapering on HAQ within the 66% tapering group.
Secondly, it was relatively short and assessors were not
blinded, in keeping with other pragmatic trials in the area.
Thirdly, it did not look at all responders to TNFi, only those
who had sustained low disease activity or remission; pa-
tients who almost achieved low disease activity may re-
spond similarly to those enrolled in the trial. Fourthly, it
only studied two TNFi, and may not apply to other TNFi.
FIG. 1 KaplanMeier curves for intention to treat analysis,
exploratory and combined tapering groups
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Fifthly, it did not consider sustained flares though there is
some evidence [32] these are more important than transi-
ent flares, nor did it assess flares from patients’ perspec-
tives, which recent research has highlighted as being
relevant [3335]. Sixthly, many patients did not wish to
participate in OPTTIRA; our non-participation rate was
substantially higher than some trials like that reported by
Moghadam et al. [11] but lower than others [8]. Similar
high non-participation rates have occurred in other RA
trials from our unit [36, 37]. This difference may represent
different ways of collecting data about screening or na-
tional differences in patients’ views on trials. However,
caution is needed when considering our results’ general-
izability. Finally, only limited information was available on
radiological outcomes.
An issue in RA treatment, particularly relevant tapering
biologics, is identifying patient sub-groups likely to re-
spond well to the treatment strategy. Analysis of pre-
dictors in the BehandelStrategiee¨n (BeSt) trial [38]
showed Anti-citrullinated protein antibody (ACPA) was
an important indicator of flares after stopping infliximab.
The impact of ACPA status on response to tapering was
also reported by Haschka et al. [10]. More recently Rech
et al. [39] showed combining ACPA status with multibio-
marker disease activity assessment predicted relapses in
over 80% of patients. An alternative is using US assess-
ments to predict response to tapering [40, 41]. There is
evidence in our trial that tapering may be best in patients
achieving deep remissions; further work is needed to clar-
ify this possibility.
The most effective and cost-effective strategy for using
biologics in RA patients remains uncertain. As current bio-
logics are not curative in established RA patients, the ra-
tionale for their indefinite use in treatment responders is
debatable. OPTTIRA shows modest tapering has no
negative clinical impacts. We consider there is sufficient
evidence for clinicians to reduce TNF inhibitor doses in
some treatment responders. This approach may be
more cost-effective than their continued use though it
risks short-term disadvantages as flares are a burden to
patients. Its impacts on disease status and healthcare
costs need further evaluation, particularly as we found
no evidence that tapering worsened patient-assessed
outcomes.
Acknowledgements
We are grateful for the many colleagues and collaborators
who contributed to the OPTTIRA trial. Trial Office Staff:
Nestor Salazar, Amaka Ejibe, Rebecca Brendell, Dr Lisa
Ann Clutterbuck, Dr Anna Kowalczyk, Beverley White-
Alao, Janice Jimenez. Trial Steering Committee:
Professor David G. I. Scott, Caroline J. Dore´, Dr Andrew
Keat, Dr Brian Tom, Dr David Collins, Professor Simon
Bowman, Ms Jacqui Deakin. Data Monitoring and Ethics
Committee: Dr Chris Deighton (Chair), Dr Richard Watts,
Professor Alex Macgregor. Principal Investigators: Dr
Anurag Bharadwaj (Basildon University Hospital),
Professor Andrew Cope (Guy’s Hospital), Dr Ira Pande
(Queens Medical Centre), Dr Sarah Levy (Croydon
University Hospital), Dr David Walker (Freeman Hospital),
Dr Michael Plant (James Cook University Hospital), Dr
Stuart Kyle (North Devon Hospital), Dr Sarah Medley
(Orpington Hospital), Dr Selwyn Richards (Poole
Hospital), Dr Clive Kelly (Queen Elizabeth Gateshead
Hospital), Dr Gerald Coakley (Queen Elizabeth Hospital,
Woolwich) Dr Nap Cheung (Queen Mary’s Hospital), Dr
James Maxwell (Rotherham General Hospital), Professor
Anthony Woolf (Royal Cornwall Hospital), Dr Richard
Haigh (Royal Devon and Exeter Hospital), Dr Karen
Walker-Bone (Royal Sussex County Hospital), Dr David
Collins (The Great Western Hospital), Dr Kirsten Mackay
(Torbay Hospital), Professor Gabrielle Kingsley (University
Hospital Lewisham). Patient Involvement: Patients were
involved in the design of the trial and a co-applicant on
the grant. One this patient was on the trial steering com-
mittee throughout the trial.
Funding: The trial was funded by Arthritis Research UK
(grant reference number 18813).
Disclosure statement: J.B.G. has received honoraria for
speaking from UCB, Pfizer, Celgene and Bristol-Myers
Squibb. All other authors have declared no conflicts of
interest.
Supplementary data
Supplementary data are available at Rheumatology
Online.
References
1 de La Forest Divonne M, Gottenberg JE, Salliot C. Safety
of biologic DMARDs in RA patients in real life: A system-
atic literature review and meta-analyses of biologic regis-
ters. Joint Bone Spine 2017;84:13340.
2 Hazlewood GS, Barnabe C, Tomlinson G et al.
Methotrexate monotherapy and methotrexate combin-
ation therapy with traditional and biologic disease mod-
ifying antirheumatic drugs for rheumatoid arthritis:
abridged Cochrane systematic review and network meta-
analysis. BMJ 2016;353:i1777.
3 Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A.
Systematic review and network meta-analysis of com-
bination and monotherapy treatments in disease-modify-
ing antirheumatic drug-experienced patients with
rheumatoid arthritis: analysis of American College of
Rheumatology criteria scores 20, 50, and 70. Biologics
2012;6:42964.
4 Galvao TF, Zimmermann IR, da Mota LM, Silva MT,
Pereira MG. Withdrawal of biologic agents in rheumatoid
arthritis: a systematic review and meta-analysis. Clin
Rheumatol 2016;35:165968.
5 Kuijper TM, Lamers-Karnebeek FBG, Jacobs JWG, Hazes
JMW, Luime JJ. Flare rate in patients with rheumatoid
arthritis in low disease activity or remission when tapering
or stopping synthetic or biologic DMARD: a systematic
review. J Rheumatol 2015;42:201222.
www.rheumatology.oxfordjournals.org 9
Optimizing treatment with TNFi in RA
Downloaded from https://academic.oup.com/rheumatology/article-abstract/doi/10.1093/rheumatology/kex315/4084282/Optimizing-treatment-with-tumour-necrosis-factor
by University College London user
on 19 October 2017
6 Navarro-Millan I, Sattui SE, Curtis JR. Systematic review
of tumor necrosis factor inhibitor discontinuation studies in
rheumatoid arthritis. Clin Ther 2013;35:185061.e1.
7 van Herwaarden N, den Broeder AA, Jacobs W et al.
Down-titration and discontinuation strategies of tumor
necrosis factor-blocking agents for rheumatoid arthritis in
patients with low disease activity. Cochrane Database
Syst Rev 2014;(9):CD010455.
8 Chatzidionysiou K, Turesson C, Teleman A et al. A multi-
centre, randomised, controlled, open-label pilot study on
the feasibility of discontinuation of adalimumab in estab-
lished patients with rheumatoid arthritis in stable clinical
remission. RMD Open 2016;2:e000133.
9 Fautrel B, Pham T, Alfaiate T et al. Step-down strategy of
spacing TNF-blocker injections for established rheuma-
toid arthritis in remission: results of the multicentre non-
inferiority randomised open-label controlled trial (STRASS:
Spacing of TNF-blocker injections in Rheumatoid ArthritiS
Study). Ann Rheum Dis 2016;75:5967.
10 Haschka J, Englbrecht M, Hueber AJ et al. Relapse rates
in patients with rheumatoid arthritis in stable remission
tapering or stopping antirheumatic therapy: interim results
from the prospective randomised controlled RETRO
study. Ann Rheum Dis 2016;75:4551.
11 Moghadam MG, Vonkeman HE, ten Klooster PM et al.
Stopping tumor necrosis factor inhibitor treatment in pa-
tients with established rheumatoid arthritis in remission or
with stable low disease activity. Arthritis Rheumatol
2016;68:18107.
12 van Herwaarden N, van der Maas A, Minten MJ et al.
Disease activity guided dose reduction and withdrawal of
adalimumab or etanercept compared with usual care in
rheumatoid arthritis: open label, randomised controlled,
non-inferiority trial. BMJ 2015;350:h1389.
13 van Vollenhoven RF, Ostergaard M, Leirisalo-Repo M et al.
Full dose, reduced dose or discontinuation of etanercept
in rheumatoid arthritis. Ann Rheum Dis 2016;75:528.
14 Yamanaka H, Nagaoka S, Lee SK et al. Discontinuation of
etanercept after achievement of sustained remission in
patients with rheumatoid arthritis who initially had mod-
erate disease activity-results from the ENCOURAGE
study, a prospective, international, multicenter rando-
mized study. Mod Rheumatol 2016;26:65161.
15 Tanaka Y, Hirata S, Kubo S et al. Discontinuation of ada-
limumab after achieving remission in patients with estab-
lished rheumatoid arthritis: 1-year outcome of the HONOR
study. Ann Rheum Dis 2015;74:38995.
16 Yoshida K, Kishimoto M, Radner H et al. Low rates of
biologic-free clinical disease activity index remission
maintenance after biologic disease-modifying anti-
rheumatic drug discontinuation while in remission in a
Japanese multicentre rheumatoid arthritis registry.
Rheumatology 2016;55:28690.
17 Yoshida K, Radner H, Mjaavatten MD et al. Incidence and
predictors of biological antirheumatic drug discontinuation
attempts among patients with rheumatoid arthritis in re-
mission: A CORRONA and NinJa Collaborative Cohort
Study. J Rheumatol 2015;42:223846.
18 Schett G, Emery P, Tanaka Y et al. Tapering biologic and
conventional DMARD therapy in rheumatoid arthritis:
current evidence and future directions. Ann Rheum Dis
2016;75:142837.
19 Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TW,
Kruger K. Dosing down with biologic therapies: a sys-
tematic review and clinicians’ perspective. Rheumatology
2017; Advance Access published 16 February 2017, doi:
10.1093/rheumatology/kew464.
20 van Gestel AM, Haagsma CJ, Riel PLCM. Validation of
rheumatoid arthritis improvement criteria that include
simplified joint counts. Arthritis Rheum 1998;41:184550.
21 NICE. Adalimumab, etanercept, infliximab, certolizumab
pegol, golimumab, tocilizumab and abatacept for
rheumatoid arthritis not previously treated with DMARDs
or after conventional DMARDs only have failed. 2016.
https://www.nice.org.uk/guidance/ta375.
22 van der Maas A, Lie E, Christensen R et al. Construct and
criterion validity of several proposed DAS28-based
rheumatoid arthritis flare criteria: an OMERACT cohort
validation study. Ann Rheum Dis 2013;72:18005.
23 van der Heijde D, Klareskog L, Landewe R et al. Disease
remission and sustained halting of radiographic progres-
sion with combination etanercept and methotrexate in
patients with rheumatoid arthritis. Arthritis Rheum
2007;56:392839.
24 van der Heijde D, Klareskog L, Rodriguez-Valverde V et al.
Comparison of etanercept and methotrexate, alone and
combined, in the treatment of rheumatoid arthritis: two-
year clinical and radiographic results from the TEMPO
study, a double-blind, randomized trial. Arthritis Rheum
2006;54:106374.
25 Silman A, Symmons D, Scott DG, Griffiths I. British Society
for Rheumatology Biologics Register. Ann Rheum Dis
2003;62(Suppl 2):ii289.
26 Joensuu JT, Huoponen S, Aaltonen KJ et al. The cost-
effectiveness of biologics for the treatment of rheumatoid
arthritis: a systematic review. PLoS One
2015;10:e0119683.
27 Stevenson M, Archer R, Tosh J et al. Adalimumab, eta-
nercept, infliximab, certolizumab pegol, golimumab, toci-
lizumab and abatacept for the treatment of rheumatoid
arthritis not previously treated with disease-modifying
antirheumatic drugs and after the failure of conventional
disease-modifying antirheumatic drugs only: systematic
review and economic evaluation. Health Technol Assess
2016;20:1610.
28 NICE. Guide to the Processes of Technology Appraisal
(PMG19). 2014. www.nice.org.uk/process/pmg19 (date
last accessed, 19 June 2017).
29 Chingcuanco F, Segal JB, Kim SC, Alexander GC.
Bioequivalence of biosimilar tumor necrosis factor-alpha
inhibitors compared with their reference biologics a sys-
tematic review. Ann Intern Med 2016;165:565.
30 Smolen JS, Emery P, Fleischmann R et al. Adjustment of
therapy in rheumatoid arthritis on the basis of achievement
of stable low disease activity with adalimumab plus
methotrexate or methotrexate alone: the randomised
controlled OPTIMA trial. Lancet 2014;383:32132.
31 Bijlsma JWJ, Welsing PMJ, Woodworth TG et al. Early
rheumatoid arthritis treated with tocilizumab, methotrex-
ate, or their combination (U-Act-Early): a multicentre,
10 www.rheumatology.oxfordjournals.org
Fowzia Ibrahim et al.
Downloaded from https://academic.oup.com/rheumatology/article-abstract/doi/10.1093/rheumatology/kex315/4084282/Optimizing-treatment-with-tumour-necrosis-factor
by University College London user
on 19 October 2017
randomised, double-blind, double-dummy, strategy trial.
Lancet 2016;388:34355.
32 Myasoedova E, Chandran A, Ilhan B et al. The role of
rheumatoid arthritis (RA) flare and cumulative burden of
RA severity in the risk of cardiovascular disease. Ann
Rheum Dis 2016;75:5605.
33 Bartlett SJ, Bykerk VP, Cooksey R et al. Feasibility and
domain validation of rheumatoid arthritis (RA) flare core
domain set: report of the OMERACT 2014 RA Flare Group
Plenary. J Rheumatol 2015;42:21859.
34 Bingham CO 3rd, Pohl C, Woodworth TG et al. Developing
a standardized definition for disease ‘‘flare’’ in rheumatoid
arthritis (OMERACT 9 Special Interest Group).
J Rheumatol 2009;36:233541.
35 Fautrel B, Morel J, Berthelot JM et al. Validation of FLARE-
RA, a self-administered tool to detect recent or current
rheumatoid arthritis flare. Arthritis Rheumatol
2017;69:30919.
36 Choy EH, Smith CM, Farewell V et al. Factorial rando-
mised controlled trial of glucocorticoids and combination
disease modifying drugs in early rheumatoid arthritis. Ann
Rheum Dis 2008;67:65663.
37 Scott DL, Ibrahim F, Farewell V et al. Tumour necrosis
factor inhibitors versus combination intensive therapy with
conventional disease modifying anti-rheumatic drugs in
established rheumatoid arthritis: TACIT non-inferiority
randomised controlled trial. BMJ 2015;350:h1046.
38 Klarenbeek NB, van der Kooij SM, Guler-Yuksel M et al.
Discontinuing treatment in patients with rheumatoid arth-
ritis in sustained clinical remission: exploratory analyses
from the BeSt study. Ann Rheum Dis 2011;70:3159.
39 Rech J, Hueber AJ, Finzel S et al. Prediction of disease
relapses by multibiomarker disease activity and autoanti-
body status in patients with rheumatoid arthritis on taper-
ing DMARD treatment. Ann Rheum Dis 2016;75:163744.
40 Alivernini S, Peluso G, Fedele AL et al. Tapering and dis-
continuation of TNF-alpha blockers without disease re-
lapse using ultrasonography as a tool to identify patients
with rheumatoid arthritis in clinical and histological re-
mission. Arthritis Res Therapy 2016;18:39.
41 Naredo E, Valor L, De la Torre I et al. Predictive value of
Doppler ultrasound-detected synovitis in relation to failed
tapering of biologic therapy in patients with rheumatoid
arthritis. Rheumatology 2015;54:140814.
www.rheumatology.oxfordjournals.org 11
Optimizing treatment with TNFi in RA
Downloaded from https://academic.oup.com/rheumatology/article-abstract/doi/10.1093/rheumatology/kex315/4084282/Optimizing-treatment-with-tumour-necrosis-factor
by University College London user
on 19 October 2017
